Sanofi gets FDA nod for blood disorder drug Cablivi

This article was originally published here

Cablivi has been approved in combination with plasma exchange and immunosuppression to treat acquired thrombotic thrombocytopenic purpura (aTTP) in adults. Cablivi is said to be the first FDA-approved

The post Sanofi gets FDA nod for blood disorder drug Cablivi appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply